EMA Digitises Submissions
- EMA is accelerating adoption of its PLM web-based electronic application form for centrally authorised products. (pharmavibes.co.uk) - PLM submissions have risen steadily since July 2024, and EMA published Rev.15 of paediatric procedural advice on April 15. (pharmavibes.co.uk) - Standardised digital submissions increase expectations for completeness, traceability, and lifecycle-management documentation. (pharmavibes.co.uk)
Europe’s drug regulator will require drugmakers to use its web-based application form for centrally authorised medicines from September 1, 2026. (plm-portal.ema.europa.eu) The European Medicines Agency said the Product Lifecycle Management, or PLM, form has been “strongly recommended” since July 2024 and will become mandatory for centrally authorised products on September 1, 2026. EMA posted the change on April 10, 2026 through its PLM portal and eSubmission site. (plm-portal.ema.europa.eu) (esubmission.ema.europa.eu) The agency said the web form allows faster automated processing and links more directly with other EMA systems used to manage product data across a medicine’s life cycle. EMA also opened a user adoption survey on April 16, 2026 as it pushes wider use of the tool. (plm-portal.ema.europa.eu) (esubmission.ema.europa.eu) An electronic application form is the cover sheet drugmakers file when they ask regulators to approve a new medicine or change an existing one. Moving that form into a structured online system gives EMA cleaner fields, fewer manual checks and data it can reuse in later regulatory steps. (plm-portal.ema.europa.eu 1) (plm-portal.ema.europa.eu 2) That shift reaches beyond formatting. Standardised online submissions tie application forms to product records, which means companies face tighter checks on whether names, manufacturing details and lifecycle history match across EMA databases. (plm-portal.ema.europa.eu 1) (plm-portal.ema.europa.eu 2) EMA’s April update landed alongside a separate revision to its paediatric filing instructions. The agency published Revision 15 of its procedural advice on paediatric applications on April 15, 2026, updating guidance for applicants working on medicines for children. (ema.europa.eu 1) (ema.europa.eu 2) Paediatric applications sit under the European Union’s Paediatric Regulation, which took effect on January 26, 2007 and requires developers of new medicines to plan or justify studies in children. EMA’s Paediatric Committee oversees much of that work, including paediatric investigation plans tied to marketing applications. (ema.europa.eu) (ema.europa.eu) (ema.europa.eu) The result is a more rigid filing environment before any scientific review begins. By September, companies seeking central approval in the European Union will need not just the right data, but the right data in the right fields. (plm-portal.ema.europa.eu) (plm-portal.ema.europa.eu)
